Search Results
Mar 03, 2026, 03:30 ET Cervoz se zúčastní veletrhu Embedded World 2026: posílení řešení Edge AI
cenu, která je navržena pro přesnost a odolnost v průmyslové komunikaci. Ta se připojuje k nové rozšiřující kartě USB typu C s funkcemi Power Delivery (PD) a DisplayPort (DP) a nejnovějšími moduly Wi-Fi 7, které poskytují
More news about: Cervoz Technology Co., Ltd.
Mar 03, 2026, 03:30 ET Cervoz wird auf der Embedded World 2026 ausstellen: Leistungsstarke Edge-KI-Lösungen
Präzision und Langlebigkeit in der industriellen Kommunikation entwickelt wurde. Hinzu kommen die neue USB Typ-C Erweiterungskarte mit Power Delivery (PD)- und DisplayPort (DP)-Funktionalität sowie die neuesten Wi-Fi 7-Module, die
More news about: Cervoz Technology Co., Ltd.
Mar 03, 2026, 03:30 ET Cervoz na targach Embedded World 2026: wsparcie dla rozwiązań Edge AI
zaprojektowaną z myślą o precyzji i trwałości w komunikacji przemysłowej. Do oferty dołącza także nowa karta rozszerzeń USB Type-C z obsługą Power Delivery (PD) i DisplayPort (DP) oraz najnowsze moduły Wi-Fi 7, zapewniające
More news about: Cervoz Technology Co., Ltd.
Mar 03, 2026, 03:30 ET Cervoz expondrá en Embedded World 2026: Impulsando soluciones de IA de vanguardia
precisión y durabilidad en las comunicaciones industriales. Esta se une a la nueva tarjeta de expansión USB Tipo-C con funcionalidad Power Delivery (PD) y DisplayPort (DP), y a los últimos módulos Wi-Fi 7, que proporcionan una
More news about: Cervoz Technology Co., Ltd.
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
cholangiocarcinoma and IDH1 inhibitor ivosidenib for previously treated IDH1-mutated disease.Additional established targeted agents include PD-1/TIGIT, HER2, TROP2, DLL4, VEGF-A, and HER2/mEGFR–directed therapies.Emerging therapies such as Tinengotinib (TransThera Sciences), Rilvegostomig
More news about: DelveInsight Business Research, LLP
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
differentiated safety profile in a Phase 1 study in combination with the anti-PD-1 cemiplimab:In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective
More news about: Biohaven Ltd.
Mar 02, 2026, 10:29 ET XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
has dosed the first participant in a Phase 1 trial of RTX-117, initially evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy participantsMilestone marks the clinical entry of a potential first-in-class therapy for CMT and VWM co-discovered
More news about: XtalPi
Mar 02, 2026, 09:10 ET XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
Emerged from PD Registrational TrialsThis pipeline extension into MSA-P also builds on XellSmart's promising clinical data in PD trials. The trials carried out at the National Centers for Neurological Disorders have enrolled more than a dozen patients with moderate to severe PD. After receiving
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Mar 02, 2026, 09:00 ET ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
randomized, double-blind, placebo-controlled, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RTX-117 in healthy participants, supporting the transition into subsequent clinical trials for patients with CMT and VWM.Advancing Treatment
More news about: ReviR Therapeutics
Mar 02, 2026, 07:00 ET Compugen Reports Fourth Quarter and Full Year 2025 Results
programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The
More news about: Compugen Ltd.
Mar 02, 2026, 00:48 ET 全新旗艦機Xiaomi 17、Xiaomi 17 Ultra 及 Leica Leitzphone powered by Xiaomi 矚目登陸香港
GPU、先進的 Qualcomm® Hexagon™ NPU、RAM 及儲存配置，足以應付最嚴苛的流動任務，輕鬆滿足用戶需求，包括高速連拍及影片錄製、高清晰度視像通話、高效率多任務處理及高負載遊戲等。Xiaomi 17 Series引入高達 100W 極速充電4，更支援 100W PD-PPS 充電，擴大了兼容充電器的選擇範圍。5Xiaomi 17 Series配備革命性的小米澎湃電池，引入新一代電源技術，採用業界領先的 16% 矽含量，實現非凡能量密度與續航能力。Xiaomi 17 Ultra 配備高達 6000mAh (典型值) 的超大電池容量，支援 90W
More news about: Xiaomi Hong Kong
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™, a proprietary T cell engager
More news about: Antengene Corporation Limited
Feb 27, 2026, 12:14 ET The Michael J. Fox Foundation for Parkinson's Research Appoints Richard Fitzgerald and Samir Kaul to Board of Directors
instrumental in supporting the Foundation's urgent mission to accelerate research, improve treatments and ultimately find a cure for Parkinson's disease (PD).
More news about: The Michael J. Fox Foundation for Parkinson's Research
Feb 26, 2026, 19:00 ET ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability
More news about: ImmVira Group
Feb 26, 2026, 16:09 ET Head and Neck Cancer Therapeutics Market to Reach USD 2.6 Billion by 2032, Driven by Immunotherapy and Precision Oncology - Credence Research Inc.
granted Breakthrough Therapy Designation for petosemtamab in combination with pembrolizumab for first-line treatment of adults with recurrent or metastatic PD-L1–positive head and neck squamous cell carcinoma (CPS ≥ 1).In March 2025, Aprea Therapeutics signed a Material Transfer Agreement with MD Anderson
More news about: Credence Research Inc.
Feb 26, 2026, 09:48 ET 再鼎醫藥公佈2025年第四季度及全年財務業績和近期公司進展
推進具有差異化優勢的全球管線，包括ZL-1503（IL-13/IL-31Rα）、ZL-6201（LRRC15 ADC）、ZL-1222（PD-1/IL-12）和ZL-1311（MUC17/CD3 TCE）– 持續推進關鍵區域性項目，KarXT在中國獲批並已啟動商業化上市籌備工作；
More news about: 再鼎醫藥
Feb 25, 2026, 20:00 ET Atomos Announces Ninja RAW 5.2" HDMI HDR Monitor-Recorder; More Info at B&H
in Apple ProRes and ProRes RAW at up to 6K30p straight to CFexpress Type B cards and USB-C storage. The Ninja RAW also features camera control, USB-C PD support, and a rich suite of monitoring tools, including EL Zone false color.Camera control covers start/stop, ISO, shutter, aperture, and white
More news about: B&H Photo
Feb 25, 2026, 09:00 ET 揭示腸道細菌與癌症治療關聯性的研究榮膺 Bial 生物醫學獎，獲頒 35 萬歐元獎金
Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors（腸胃道微生物群影響以 PD-1 為基礎的免疫療法對上皮性腫瘤之療效）的獲獎研究，在兩位蜚聲國際的法國知名學者 Laurence Zitvogel（古斯塔夫•魯西癌症研究院與巴黎-薩克雷大學）及 Guido Kroemer（古斯塔夫•魯西癌症研究院和巴黎西岱大學）領導之下完成。這項獲獎研究記錄了近年來在多項癌症治療中其中一項最重要的進展，它證實了腸胃道微生物群（gut
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET 장내 박테리아와 암 치료의 연관성 규명한 연구, 비알 생의학상 수상 및 35만 유로 상금 받아
수상 시험인 장내 미생물군이 상피세포암에 대한 PD-1 기반 면역요법의 유효성에 미치는 영향(Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors)은 구스타브 루시와 파리-사클레 대학교 소속 로렌스 지트보겔(Laurence Zitvogel)
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET El descubrimiento que vincula las bacterias intestinales con el tratamiento contra el cáncer gana el premio Bial en Biomedicina y recibe un galardón de 350.000 euros
Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumor (El microbioma intestinal influye en la eficacia de la inmunoterapia basada en PD-1 contra los tumores epiteliales), está dirigido por el dúo de investigación Laurence
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Une découverte liant les bactéries intestinales au traitement du cancer remporte le prix Bial Award in Biomedicine et se voit attribuer une somme de 350 000 EUR
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors (Comment le microbiome intestinal influence l'efficacité de l'immunothérapie anti-PD1 contre les tumeurs épithéliales), a été dirigée par le duo de chercheurs Laurence
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET 腸内細菌とがん治療の関連を解明した発見が「BIAL生物医学賞（BIAL Award in Biomedicine）」を受賞、35万ユーロを獲得
受賞研究である「Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors」は、国際的に著名なフランス人研究者であるLaurence Zitvogel氏（Gustave Roussy and Paris-Saclay University）およびGuido
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
The winning study, Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors, is led by research duo Laurence Zitvogel (Gustave Roussy and Paris-Saclay University) and
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Descoberta ligando bactérias intestinais ao tratamento do câncer vence o Prêmio Bial em Biomedicina e recebe € 350.000
Microbioma intestinal influencia a eficácia da imunoterapia baseada em PD‑1 contra tumores epiteliais, é liderado pela dupla de pesquisadores Laurence Zitvogel (Gustave Roussy e Universidade Paris-Saclay) e Guido
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET Entdeckung zum Zusammenhang zwischen Darmbakterien und Krebstherapie gewinnt den Bial Award in Biomedicine und erhält 350.000 Euro Preisgeld
Die prämierte Studie mit dem Titel „Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors" wird von dem Forschungsduo Laurence Zitvogel (Gustave Roussy und Université Paris-Saclay) und Guido
More news about: Bial Foundation